News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Catalyst Pharmaceutical Partners, Inc. Release: Scientific Paper Describing the Ocular Safety of Short-Term Vigabatrin Treatment for Cocaine Addiction in Online Edition of American Journal of Ophthalmology



6/28/2012 9:24:16 AM

CORAL GABLES, Fla., June 28, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that an ePublication on CPP-109 (vigabatrin) describing ocular safety results obtained with CPP-109 (vigabatrin) was published in the June 14, 2012 web edition of the American Journal of Ophthalmology (AJO). These results were obtained from the Company's previously completed Phase II(a), randomized, double-blind, placebo-controlled trial in cocaine addicted subjects.The paper is entitled, "Visual Field and Ocular Safety during Short-Term Vigabatrin Treatment in Cocaine Abusers" by Tamara L. Berezina, Albert S. Khouri, M. Douglas Winship and Robert D. Fechtner.

Read at GlobeNewswire


comments powered by Disqus
   
Addiction

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES